← Back to Compounds
oralanabolic

Desoxymethyltestosterone

DMTMadol17α-methyl-5α-androst-2-en-17β-ol
187
Anabolic Ratio
74
Androgenic Ratio
0.33d
Half-Life

Designer AAS developed by Patrick Arnold (BALCO scandal). First identified in an athlete's sample in 2003, leading to one of the most significant doping scandals in sports history. Not a natural steroid derivative — purely synthetic. Limited clinical data due to its illicit nature.

Mechanism of Action

5α-androstane derivative lacking the C3-keto group. AR agonist despite atypical structure. 17α-methyl group provides oral bioavailability. Does not aromatize. Resists metabolism by 3α-HSD (unlike DHT), preserving androgenic activity in muscle. Unique detection challenge: early immunoassay screens failed to detect it due to unusual structure.

Desoxymethyltestosterone molecule
Molecular structure

Typical Dosing

70 mg
low / week
140 mg
moderate / week
280 mg
high / week

⚠ Warning Flags

  • BALCO-origin designer steroid — Schedule III in the US
  • Very limited human safety data
  • Positive doping test has ended multiple major athletic careers

Effect Profile

Muscle Protein Synthesis
5Moderate
Nitrogen Retention
5Moderate
Strength Gains
6Moderate
Red Blood Cell Production
3Low
Fat Loss
3Low
Glycogen Storage
5Moderate
Recovery Speed
5Moderate
Collagen Synthesis
3Low

Side Effect Profile

Hormonal Suppression
6Moderate
Estrogenic Effects
2Minimal
Androgenic Effects
4Low
Cardiovascular Strain
5Moderate
Liver Stress
6Moderate
Insulin Resistance
3Low
Mood Changes
4Low
Prostate Risk
3Low

Research Studies

Tetrahydrogestrinone: discovery, synthesis, and detection in urine

Catlin DH, et al. · 2004

PubMed

USADA/UCLA lab analysis that uncovered the BALCO designer steroid program; desoxymethyltestosterone (Madol) was identified alongside THG in athlete samples, with the report documenting its AR binding and pharmacological properties.